Aravive, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies that disrupt the GAS6-AXL signaling pathway, a key driver of tumor progression, metastasis and treatment resistance. The company’s lead product candidate, batiraxcept (AVB-500), is a recombinant fusion protein designed to sequester the growth arrest–specific 6 (GAS6) ligand and prevent activation of the AXL receptor tyrosine kinase. By neutralizing GAS6, batiraxcept aims to sensitize tumors to standard-of-care chemotherapies and targeted agents, with initial clinical development centered on platinum-resistant ovarian cancer and other solid tumors.
In addition to its lead oncology program, Aravive is advancing preclinical candidates that leverage the same GAS6-AXL axis to address fibrotic diseases of the liver and kidneys. These collaborative research efforts seek to extend the therapeutic potential of AXL pathway inhibition beyond oncology into chronic organ fibrosis, where unchecked fibroblast activation and inflammation contribute to progressive tissue damage. Aravive’s scientific team employs a combination of proprietary binding assays and in vivo models to characterize pharmacodynamics, safety and efficacy for both cancer and fibrotic indications.
Founded in 2016 and headquartered in Houston, Texas, Aravive originated as a spin-out to translate academic discoveries around AXL biology into clinical applications. Since its inception, the company has built a comprehensive development platform encompassing CMC (Chemistry, Manufacturing and Controls), translational biomarkers and regulatory strategy. Aravive has engaged with global regulatory agencies to design adaptive Phase 1 and 2 studies, and it has established manufacturing partnerships to support scalable production of its fusion protein constructs.
Aravive maintains operations in the United States and collaborates with academic centers and industry partners across North America, Europe and Asia to advance its clinical trials. The executive leadership team brings together seasoned professionals with backgrounds in oncology drug development, biologics manufacturing and global regulatory affairs. Under their guidance, Aravive is committed to delivering first-in-class and best-in-class therapies for patients with high unmet medical needs in both oncology and fibrotic diseases.
AI Generated. May Contain Errors.
Free ARAV Stock Alerts